A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/00 (2006.01) A41D 7/00 (2006.01) A61K 38/17 (2006.01) A61K 39/165 (2006.01) A61M 5/178 (2006.01)
Patent
CA 2276219
The present immunotherapy relates to a method of treating epithelial tumors and the pharmaceutical compositions and kits useful in treating such tumors. The immunotherapy comprises injecting an effective amount of a pharmaceutical composition containing at least one antigen into the tumor, wherein the antigen is selected for inducing or having the ability to induce a cutaneous delayed type hypersensitivity (DTH) response in the subject prior to the injection of the antigen into the tumors. This immunotherapy is particularly useful in treating epithelial tumors, such as warts or verrucae, that are induced by or related to papillomavirus. Antigens useful in the present immunotherapy are anergy panel antigens, such as killed mumps virus, candida extract, trichophyton extract or comparable antigenic extracts. Additionally, the method optionally includes the injection of an effective amount of at least one cytokine or colony stimulating factor into the tumor either simultaneously with or sequentially to the injection of the antigen. The subject treated by the present immunotherapy is preferably a mammal selected from a human, canine, bovine, feline, equine, ovine or rabbit subject.
Horn Thomas Dag
Johnson Sandra Marchese
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Board Of Trustees Of The University Of Arkansas
LandOfFree
Immunotherapy of epithelial tumors using intralesional... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapy of epithelial tumors using intralesional..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy of epithelial tumors using intralesional... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1918025